# EDGAR Filing Document

**Accession Number:** 0000884624
**File Stem:** 0001193125-26-205003
**Filing Date:** 2026-5
**Character Count:** 148492
**Document Hash:** 4067f4dfe7309e5178ab8a3df8823aaf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-205003.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001193125-26-205003

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 78

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Orthofix Medical Inc.
- **CENTRAL INDEX KEY:** 0000884624
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **FISCAL YEAR END:** 1223

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19961
- **FILM NUMBER:** 26940385

**BUSINESS ADDRESS:**
- **STREET 1:** 3451 PLANO PARKWAY
- **CITY:** LEWISVILLE
- **STATE:** TX
- **ZIP:** 75056
- **BUSINESS PHONE:** 214-937-2000

**MAIL ADDRESS:**
- **STREET 1:** 3451 PLANO PARKWAY
- **CITY:** LEWISVILLE
- **STATE:** TX
- **ZIP:** 75056

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORTHOFIX INTERNATIONAL N V
- **DATE OF NAME CHANGE:** 19970708

?xml version='1.0' encoding='ASCII'? 10-Q

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, DC 20549** 

------

**FORM** 10-Q

------

**(Mark one)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended** **March 31,** 2026

**OR** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to .** 

**Commission File Number:** 0-19961

------

![img134518077_0.jpg](img134518077_0.jpg)

ORTHOFIX MEDICAL INC.

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| Delaware | 98-1340767 |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |
| 3451 Plano Parkway**,**<br>Lewisville**,** Texas | 75056 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(**214**)** 937-2000

**(Registrant's telephone number, including area code)** 

**Not applicable**

**(Former name, former address and former fiscal year, if changed since last report)** 

------

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-Accelerated filer | ☐ | Smaller Reporting Company | ☐ |
|  |  | Emerging Growth Company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of May 1, 2026, 40,421,652 shares of common stock were issued and outstanding.

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, $0.10 par value per share | OFIX | Nasdaq Global Select Market |

---

------

**Table of Contents**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| PART I | [<u>FINANCIAL INFORMATION</u>](#financial_information) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 1. | [<u>Financial Statements</u>](#condensed_consolidated_financial_stateme) | 4 |
|  | [<u>Condensed Consolidated Balance Sheets as of March 31, 2026, and December 31, 2025</u>](#condensed_consolidated_balance_sheets) | 4 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026, and 2025</u>](#condensed_consolidated_statements_of_ope) | 5 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Changes in Shareholders' Equity for the three months ended March 31, 2026, and 2025</u>](#cndnsd_consldtd_stmts_shareholder_equity) | 6 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026, and 2025</u>](#condensed_consolidated_statements_of_cas) | 7 |
|  | [<u>Notes to the Unaudited Condensed Consolidated Financial Statements</u>](#notes_to_condensed_consolidated_financia) | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 2. | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#managements_discussion_and_analysis) | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 3. | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#quantitative_and_qualitative_disclosures) | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 4. | [<u>Controls and Procedures</u>](#controls_and_procedures) | 29 |
| PART II | [<u>OTHER INFORMATION</u>](#part_ii_or_information) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 1. | [<u>Legal Proceedings</u>](#item_1_legal_proceedings) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 1A. | [<u>Risk Factors</u>](#item_1a_risk_factors) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item_2_unregistered_sales_equity_securit) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 3. | [<u>Defaults Upon Senior Securities</u>](#item_3_defaults_upon_senior_securities) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 4. | [<u>Mine Safety Disclosures</u>](#item_4_mine_safety_disclosures) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 5. | [<u>Other Information</u>](#item_5_or_information) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 6. | [<u>Exhibits</u>](#item_6_exhibits) | 30 |
| [<u>SIGNATURES</u>](#signatures) | [<u>SIGNATURES</u>](#signatures) | 32 |

---

------

**Forward-Looking Statements**

This quarterly report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts, and projections. All statements, other than statements of historical fact, contained in this report, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "projects," "intends," "predicts," "potential," "positioned," "deliver," or "continue" or other comparable terminology. Forward-looking statements include, but are not limited to, statements about:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our intentions, beliefs, and expectations regarding our operations, sales, expenses, and future financial performance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our operating results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our plans for future products and enhancements of existing products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•anticipated growth and trends in our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the timing of, and our ability to maintain and obtain, regulatory clearances or approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our belief that our cash and cash equivalents, investments, and access to our credit facilities will be sufficient to satisfy our anticipated cash requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding our revenues, customers, and distributors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to persuade surgeons to use our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to attract and retain distributors and/or sales and other personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding our costs, suppliers, and manufacturing abilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our beliefs and expectations regarding our market penetration and expansion efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our anticipated trends and challenges in the markets in which we operate; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations and beliefs regarding, and the impact of, investigations, claims, and litigation.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, estimates, and assumptions that are difficult to predict. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in forward-looking statements. Potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to, those set forth in Part I, Item 1A under the heading *Risk Factors* of our Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 10-K"); Part II, Item 7 *Management's Discussion and Analysis of Financial Condition and Results of Operations* of the 2025 10-K*;* and elsewhere throughout the 2025 10-K, and in our reports filed with the U.S. Securities and Exchange Commission (the "SEC") subsequent to the date we filed the 2025 10-K with the SEC. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement in this report speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. Except as required by law, we undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.

**Trademarks**

Solely for convenience, our trademarks and trade names in this report are referred to without the® and™ symbols, but such references should not be construed as any indicator that we will not assert, to the fullest extent under applicable law, our rights thereto.

------

**PART I. FINANCIAL INFORMATION** 

**<u>I</u><u>tem 1. Financial Statements</u>** 

**ORTHOFIX MEDICAL INC.** 

**Condensed Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| **(U.S. Dollars, in thousands, except par value data)** | **March 31,<br>2026** | **December 31,<br>2025** |
|  | **(Unaudited)** |  |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $120278 | $82025 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 592 | 3090 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances of $8,990 and $8,308, respectively | 137775 | 135746 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 177818 | 172319 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 25057 | 23667 |
| Total current assets | 461520 | 416847 |
| Property, plant, and equipment, net | 125327 | 129399 |
| Intangible assets, net | 69336 | 72765 |
| Goodwill | 194934 | 194934 |
| Other long-term assets | 35484 | 36702 |
| **Total assets** | $**886601** | $**850647** |
| **Liabilities and shareholders' equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $54686 | $58392 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of finance lease liability | 115 | 837 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 106232 | 111253 |
| Total current liabilities | 161033 | 170482 |
| Long-term debt | 221335 | 157391 |
| Long-term portion of finance lease liability | 12937 | 17060 |
| Other long-term liabilities | 56110 | 55677 |
| Total liabilities | 451415 | 400610 |
| Contingencies (Note 7) |  |  |
| Shareholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common shares $0.10 par value; 100,000 shares authorized;<br>&nbsp;&nbsp;&nbsp;&nbsp;40,382 and 39,834 issued and outstanding as of March 31,<br>&nbsp;&nbsp;&nbsp;&nbsp;2026, and December 31, 2025, respectively | 4038 | 3983 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 820247 | 813769 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (389241) | (368333) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 142 | 618 |
| Total shareholders' equity | 435186 | 450037 |
| **Total liabilities and shareholders' equity** | $**886601** | $**850647** |

---

*The accompanying notes form an integral part of these condensed consolidated financial statements.* 

------

**ORTHOFIX MEDICAL INC.** 

**Condensed Consolidated Statements of Operations and Comprehensive Loss**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| **(Unaudited, U.S. Dollars, in thousands, except per share data)** | **2026** | **2025** |
| Net sales | $196708 | $193646 |
| Cost of sales | 57162 | 72027 |
| Gross profit | 139546 | 121619 |
| &nbsp;&nbsp;Sales, general, and administrative | 134911 | 132981 |
| &nbsp;&nbsp;Research and development | 15320 | 19766 |
| &nbsp;&nbsp;Acquisition-related amortization, impairment, and remeasurement (Note 11) | 3751 | 17745 |
| Operating loss | (14436) | (48873) |
| &nbsp;&nbsp;Interest expense, net | (5664) | (4506) |
| &nbsp;&nbsp;Other income (expense), net | (734) | 1246 |
| Loss before income taxes | (20834) | (52133) |
| Income tax expense | (74) | (961) |
| **Net loss** | $**(20908)** | $**(53094)** |
| Net loss per common share: |  |  |
| &nbsp;&nbsp;Basic | $(0.52) | $(1.35) |
| &nbsp;&nbsp;Diluted | (0.52) | (1.35) |
| Weighted average number of common shares: |  |  |
| &nbsp;&nbsp;Basic | 40450 | 39188 |
| &nbsp;&nbsp;Diluted | 40450 | 39188 |
| Other comprehensive income (loss), before tax |  |  |
| &nbsp;&nbsp;Currency translation adjustment | (476) | 1746 |
| Other comprehensive income (loss), before tax | (476) | 1746 |
| &nbsp;&nbsp;Income tax expense related to other comprehensive income (loss) |  |  |
| Other comprehensive income (loss), net of tax | (476) | 1746 |
| **Comprehensive loss** | $**(21384)** | $**(51348)** |

---

*The accompanying notes form an integral part of these condensed consolidated financial statements.*

------

**ORTHOFIX MEDICAL INC.** 

**Condensed Consolidated Statements of Changes in Shareholders' Equity** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **(Unaudited, U.S. Dollars, in thousands)** | **Number of<br>Common<br>Shares<br>Outstanding** | **Common<br>Shares** | **Additional<br>Paid-in<br>Capital** | **Accumulated Deficit** | **Accumulated<br>Other<br>Comprehensive Income (Loss)** | **Total<br>Shareholders'<br>Equity** |
| **At December 31, 2025** | 39834 | $3983 | $813769 | $(368333) | $618 | $450037 |
| Net loss |  |  |  | (20908) |  | (20908) |
| Other comprehensive loss, net of tax |  |  |  |  | (476) | (476) |
| Share-based compensation expense |  |  | 6533 |  |  | 6533 |
| Common shares issued, net | 548 | 55 | (55) |  |  |  |
| **At March 31, 2026** | **40382** | $**4038** | $**820247** | $**(389241)** | $**142** | $**435186** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **(Unaudited, U.S. Dollars, in thousands)** | **Number of<br>Common<br>Shares<br>Outstanding** | **Common<br>Shares** | **Additional<br>Paid-in<br>Capital** | **Accumulated Deficit** | **Accumulated<br>Other<br>Comprehensive Income (Loss)** | **Total<br>Shareholders'<br>Equity** |
| **At December 31, 2024** | 38486 | $3849 | $779718 | $(276141) | (4302) | $503124 |
| Net loss |  |  |  | (53094) |  | (53094) |
| Other comprehensive income, net of tax |  |  |  |  | 1746 | 1746 |
| Share-based compensation expense |  |  | 6469 |  |  | 6469 |
| Common shares issued, net | 610 | 61 | (12) |  |  | 49 |
| **At March 31, 2025** | **39096** | $**3910** | $**786175** | $**(329235)** | $**(2556)** | $**458294** |

---

*The accompanying notes form an integral part of these condensed consolidated financial statements.*

------

**ORTHOFIX MEDICAL INC.**

**Condensed Consolidated Statements of Cash Flows**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Cash flows from operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(20908) | $(53094) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash from operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation, amortization, and impairment | 13493 | 34431 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory reserve expenses | 2900 | 15301 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of operating lease assets, debt costs, and other assets | 1058 | 1251 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for expected credit losses | 719 | 1058 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 93 | 445 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 6533 | 6469 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of fixed assets | 331 | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in valuation of investment securities | (16) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 750 | (610) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (178) | (1347) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (2964) | 2379 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (8845) | 693 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (1459) | 141 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (4368) | (2493) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | (5221) | (21385) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets and liabilities | 472 | (1655) |
| **Net cash used in operating activities** | **(17610)** | **(18391)** |
| Cash flows from investing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (10661) | (6736) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other investing activities | 146 |  |
| **Net cash used in investing activities** | **(10515)** | **(6736)** |
| Cash flows from financing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common shares |  | 49 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments related to finance lease obligation | (31) | (188) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from credit facility | 64025 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of debt issuance costs and other financing activities | (24) | (512) |
| **Net cash provided by (used in) financing activities** | **63970** | **(651)** |
| Effect of exchange rate changes on cash | (90) | 493 |
| Net change in cash and cash equivalents | 35755 | (25285) |
| Cash, cash equivalents, and restricted cash at the beginning of period | 85115 | 85738 |
| **Cash, cash equivalents, and restricted cash at the end of period** | $**120870** | $**60453** |
| **Components of cash, cash equivalents, and restricted cash at the end of period** |  |  |
| Cash and cash equivalents | $120278 | $57953 |
| Restricted cash | 592 | 2500 |
| **Cash, cash equivalents, and restricted cash at the end of period** | $**120870** | $**60453** |
| Noncash investing activities - Accrued purchases of capital expenditures | $13524 | $5618 |
| Noncash investing activities - Purchase of intangible assets |  | 40 |

---

*The accompanying notes form an integral part of these condensed consolidated financial statements.*

------

**ORTHOFIX MEDICAL INC.** 

**Notes to the Unaudited Condensed Consolidated Financial Statements**

**1. Business and basis of presentation**

*Description of the Business*

Orthofix Medical Inc. (the "Company" or "Orthofix") is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company delivers technology-enabled solutions that support improved clinical outcomes and more efficient care across the continuum. Orthofix offers a focused and differentiated portfolio spanning spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System.

*Basis of Presentation*

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair statement have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company's 2025 Form 10-K. Operating results for the three months ended March 31, 2026, are not necessarily indicative of the results that may be expected for other interim periods or the year ending December 31, 2026.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition; contractual allowances; allowances for expected credit losses; inventories; valuation of intangible assets; goodwill; fair value measurements, including contingent consideration; litigation and contingent liabilities; tax matters; and share-based compensation. Actual results could differ from these estimates.

------

**2. Recently adopted accounting standards and recently issued accounting pronouncements**

*Recently Issued Accounting Pronouncements*

---

| | | | |
|:---|:---|:---|:---|
| **Topic** | **Description of Guidance** | **Effective Date** | **Status of Company's Evaluation** |
| *Disclosure Improvements - Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (Accounting Standard Update "ASU" 2023-06)* | Adds interim and annual disclosure requirements to a variety of subtopics in the Accounting Standards Codification, including those focusing on accounting changes, earnings per share, debt, and repurchase agreements. The guidance will be applied prospectively. The effective date will be the date when the SEC's removal of the related disclosure requirement becomes effective, with early adoption prohibited. | Various | The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. |
| *Disaggregation of Income Statement Expenses (ASU 2024-03)* | Improves financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the financial statements at interim and annual reporting periods. The amendments are to be applied prospectively to financial statements issued for reporting periods after the effective date or retrospectively to all prior periods presented in the financial statements. | January 1, 2027 | The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. |
| *Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06)* | Aligns the accounting for internal-use software with how software is developed to increase the operability of the recognition and capitalization of internal-use software costs in accordance with Subtopic 350-40. Early adoption is permitted as of the beginning of an annual reporting period. The guidance is to be applied prospectively to new software costs incurred as of the beginning of the adoption period for all projects, including in-process projects. | January 1, 2028 | The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. |
| *Narrow-Scope Requirements for Interim Reporting (ASU 2025-11)* | Clarifies interim disclosure requirements and applicability of Topic 270, *Interim Reporting* for events since the end of the last annual reporting period that have a material impact on the entity. Early adoption is permitted and the amendments are to be applied prospectively or retrospectively to any or all periods presented in the financial statements. | January 1, 2028 | The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. |

---

Other recently issued ASUs, excluding those ASUs which have already been disclosed as adopted or described above, were assessed and determined not applicable, or are expected to have minimal impact on the Company's condensed consolidated financial statements.

------

**3. Inventories** 

Inventories were as follows:

---

| | | |
|:---|:---|:---|
| **(U.S. Dollars, in thousands)** | **March 31,<br>2026** | **December 31,<br>2025** |
|  | (Unaudited) |  |
| Raw materials | $24882 | $22865 |
| Work-in-process | 65194 | 63255 |
| Finished products | 87742 | 86199 |
| Inventories | $177818 | $172319 |

---

**4. Leases**

A summary of the Company's lease portfolio as of March 31, 2026, and December 31, 2025, is presented in the table below:

---

| | | | |
|:---|:---|:---|:---|
| **(U.S. Dollars, in thousands)** | **Classification** | **March 31,<br>2026** | **December 31,<br>2025** |
|  |  | (Unaudited) |  |
| **Assets** | **Assets** |  |  |
| Operating leases | Other long-term assets | $21571 | $22279 |
| Finance leases | Property, plant, and equipment, net | 9460 | 14442 |
| Total lease assets |  | $31031 | $36721 |
| **Liabilities** |  |  |  |
| Current |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases | Other current liabilities | $3108 | $3147 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance leases | Current portion of finance lease liability | 115 | 837 |
| Long-term |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases | Other long-term liabilities | 24760 | 25413 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance leases | Long-term portion of finance lease liability | 12937 | 17060 |
| Total lease liabilities |  | $40920 | $46457 |

---

Supplemental cash flow information related to leases was as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Cash paid for amounts included in the measurement of lease liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows from operating leases | $2206 | $2371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows from finance leases | 364 | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing cash flows from finance leases | 31 | 188 |
| ROU assets obtained in exchange for lease obligations |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases | 87 | 231 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance leases |  |  |

---

------

**5. Long-term debt**

The carrying values of the Company's outstanding debt obligations as of March 31, 2026, and December 31, 2025, were as follows:

---

| | | |
|:---|:---|:---|
| **(U.S. Dollars, in thousands)** | **March 31,<br>2026** | **December 31,<br>2025** |
|  | (Unaudited) |  |
| *Outstanding Term Loans* |  |  |
| Principal amount | $225000 | $160000 |
| Unamortized original debt discount | (2630) | (1839) |
| Unamortized debt issuance costs and lenders fees | (1035) | (770) |
| Total indebtedness from outstanding term loans | $221335 | $157391 |
| Current portion of long-term debt | $— | $— |
| Long-term debt | 221335 | 157391 |
| **Total indebtedness outstanding** | $221335 | $157391 |

---

On November 7, 2024, the Company, as borrower, and its U.S. subsidiaries entered into a $275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including Oxford, K2 HealthVentures LLC, and HSBC Ventures USA Inc. The Credit Agreement provides for a $160.0 million senior secured term loan (the "Initial Term Loan") and a $65.0 million senior secured delayed draw term loan facility (the "Term B Loan"). In addition, at Oxford's discretion, an additional $50.0 million of draw capacity is available through January 1, 2029 (the "Term C Loan" and, collectively with the Term B Loan and the Initial Term Loan, the "Credit Facilities").

On January 15, 2026, the Company borrowed $65.0 million via the Term B Loan to provide capital flexibility ahead of the expiration of the tranche. The Credit Facilities, to the extent ultimately drawn, will each mature in November 2029, following an interest-only payment period ending December 2028, and monthly amortization of principal and accrued interest between January 2029 and November 2029. The Credit Agreement contains financial covenants requiring the Company to maintain (i) a minimum level of liquidity at all times and (ii) a maximum total debt-to-EBITDA leverage ratio (measured on a quarterly basis) during the term of the facility. As of March 31, 2026, the Company was in compliance with all required financial covenants.

As of March 31, 2026, the Company had no borrowings on its available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($6.4 million).

**6. Fair value measurements and investments**

The fair value measurements of the Company's financial assets and liabilities measured on a recurring basis were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **March 31,<br>2026** | **March 31,<br>2026** | **March 31,<br>2026** | **March 31,<br>2026** | **December 31,<br>2025** |
| **(U.S. Dollars, in thousands)** | **Level 1** | **Level 2** | **Level 3** | **Total** | **Total** |
|  |  |  |  | (Unaudited) |  |
| Liabilities |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Lattus Contingent Consideration | $— | $— | $8680 | $8680 | $7930 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred compensation plan |  | 1634 |  | 1634 | 1720 |
| Total | $— | $1634 | $8680 | $10314 | $9650 |

---

*Lattus Contingent Consideration*

In connection with the merger with SeaSpine Holdings Corporation ("SeaSpine") in 2023 (the "Merger"), the Company assumed a contingent consideration obligation under a purchase agreement between SeaSpine and Lattus Spine LLC ("Lattus") executed in December 2022. Under the terms of this agreement, the Company may be required to make installment payments to Lattus (the "Lattus Contingent Consideration") at certain dates based on future net sales of certain products (the "Lateral Products").

The estimated fair value of the Lattus Contingent Consideration is determined using a Monte Carlo simulation and a discounted cash flow model requiring significant inputs which are not observable in the market. The significant inputs include assumptions related to the estimated future sales of Lateral Products, revenue risk-adjusted discount rates, revenue volatility, and discount rates matched

------

to the timing of payments. The following table provides a reconciliation of the beginning and ending balances for the Lattus Contingent Consideration measured at estimated fair value using significant unobservable inputs (Level 3):

---

| | | |
|:---|:---|:---|
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Lattus Contingent Consideration estimated fair value at January 1 | $7930 | $15400 |
| Change in fair value recognized in acquisition-related amortization, impairment, and remeasurement | 750 | (610) |
| Lattus Contingent Consideration estimated fair value at March 31 | $8680 | $14790 |

---

The estimated fair value of the Lattus Contingent Consideration as of March 31, 2026, was $8.7 million; however, the actual amount ultimately paid could be higher or lower. As of March 31, 2026, the Company classified the remaining Lattus Contingent Consideration of $4.7 million and $4.0 million within other current liabilities and other long-term liabilities, respectively.

The following table provides quantitative information related to certain key assumptions utilized within the valuation as of March 31, 2026:

---

| | | | |
|:---|:---|:---|:---|
| **(Unaudited, U.S. Dollars, in thousands)** | **Fair Value as of<br> March 31, 2026** | **Unobservable inputs** | **Estimate** |
| Lattus Contingent Consideration | $8680 | Counterparty discount rates | 13.0% |
|  |  | Revenue risk-adjusted discount rates | 6.4% - 6.5% |

---

**7. Commitments and Contingencies** 

*Arbitration claims with former executives*

In September 2023, the Company's Board of Directors (the "Board") terminated the employment of Keith Valentine, John Bostjancic, and Patrick Keran, who had served respectively as the Company's President and Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer (collectively, the "Former Executives"). The Board's decision followed an investigation conducted by independent outside legal counsel and directed and overseen by a committee of certain of the Company's independent directors. At the time of termination, the Company notified each of the Former Executives that their respective terminations of employment were being made for "Cause," as such term is defined in applicable employment-related agreements (including each executive's respective Change in Control and Severance Agreement, dated June 19, 2023 (the "CIC and Severance Agreements"). The Former Executives subsequently made claims against the Company in arbitration in the State of California, asserting breach of contract because each of them was entitled to the severance payments and other equity-based rights that would be owed to them if their respective termination had been made "without Cause" under the CIC and Severance Agreements, and further asserting damages for purported defamation, false light invasion of privacy, and deceit, as well as indemnification and advancement for attorneys' fees.

On January 26, 2026, the arbitrator in Mr. Valentine's matter issued a decision denying Mr. Valentine's defamation, false light invasion of privacy, and deceit claims, and his indemnification of fees claim. Based on the evidence presented during the arbitration process, the arbitrator found that Mr. Valentine's conduct met the legal definition of "acts of moral turpitude" and that the public statements that the Company made about Mr. Valentine in a press release and filings with the SEC subsequent to the termination of his employment were true. Although Mr. Valentine's conduct was found to meet the legal definition of "acts of moral turpitude" for purposes of his defamation and other tort claims, and although engaging in "material acts of moral turpitude" would constitute "Cause" under the CIC and Severance Agreement, the arbitrator maintained his preliminary decision issued on October 2, 2025, finding that (i) Mr. Valentine's conduct prior to his entry into the CIC and Severance Agreement on June 19, 2023 could not be considered for purposes of determining whether "Cause" existed under such agreement, and (ii) his conduct between that date and his termination of employment on September 11, 2023, did not amount to "Cause". As a result, the arbitrator issued an interim award to Mr. Valentine for breach of contract damages in the amount of $11.8 million, finding such amount to be equivalent to the severance and equity-based rights that Mr. Valentine would have received in a "without Cause" termination. The arbitrator also awarded accrued interest, at the pre-judgment interest rate of 10% under California law. On April 22, 2026, the Company made a

------

payment in satisfaction of the arbitrator's interim award plus accrued interest, in the amount of $14.8 million. The arbitrator's final order confirming the interim award and determining attorneys' fees payable, is expected in the second quarter of 2026.

On April 15, 2026, Mr. Keran's arbitration claims were settled for $4.25 million. On April 22, 2026, the Company and Mr. Bostjancic entered into a settlement agreement covering all of Mr. Bostjancic's claims, in the amount of $4.25 million. As of March 31, 2026, the Company had accrued $23.3 million related to the arbitration matters with the Former Executives.

In addition to the Former Executives' arbitration claims, in September 2024, Messrs. Valentine, Bostjancic and Keran filed an action in California State Court against former director and interim CEO Catherine Burzik and current director Wayne Burris, seeking relief for, among other things, alleged defamation, false light invasion of privacy, intentional misrepresentation, false promise, and tortious interference with contract. Mr. Bostjancic has agreed to dismiss his claims in this action in connection with his settlement agreement. The Company disagrees with the allegations contained in the action against Ms. Burzik and Mr. Burris and will continue vigorously defending the asserted claims. The Company currently cannot reasonably estimate a possible loss, or range of loss, that may arise from the action.

*Securities class action complaints*

On August 21, 2024, a securities class action complaint captioned Bernal v. Orthofix Medical Inc., et al., Case No. 24-cv-00690, was filed in the United States District Court for the Eastern District of Texas (the "Bernal Complaint"). The plaintiff, a purported Company shareholder, alleges through the complaint violations of Sections 10(b) and 20(a) of the Exchange Act, and SEC Rule 10b-5 promulgated thereunder, and names as defendants the Company and the following former Company directors and officers: Jon Serbousek (former director and former President and Chief Executive Officer), Keith Valentine (former director and former President and Chief Executive Officer), John Bostjancic (former Chief Financial Officer), and Patrick Keran (former Chief Legal Officer). The complaint alleges that the Company made, and the named former directors and officers caused the Company to make, materially false and misleading statements between October 11, 2022, and September 12, 2023, that, according to the complaint, falsely assured the market of Messrs. Valentine, Bostjancic, and Keran's respective commitments to, among other things, ethical and legal standards and corporate responsibility.

On September 6, 2024, a securities class action complaint captioned O'Hara v. Orthofix Medical Inc., et al., Case No. 24-cv-01593, was filed in the United States District Court for the Southern District of California (the "O'Hara Complaint"). The plaintiff, a purported former shareholder of SeaSpine at the time of the Merger, alleges through the complaint violations of Sections 11, 12 and 15 of the Securities Act, and names most of the same defendants as the Bernal Complaint, as well as certain additional current and/or former Company directors and officers. The complaint makes similar assertions to the Bernal complaint, and alleges that the Company's registration statement on Form S-4 filed in 2022 in connection with the Merger, as well as related written and oral offering materials, contained untrue statements of material fact and material omissions, including, among other things, with respect to the effectiveness of the Company's internal controls. On November 26, 2024, the O'Hara Complaint was transferred to the Eastern District of Texas, and on December 11, 2024, the O'Hara Complaint was consolidated with the Bernal Complaint. On April 17, 2025, the plaintiffs filed an amended complaint in the consolidated action, captioned In re Orthofix Medical Inc. Securities Litigation, with substantially the same allegations contained in the Bernal Complaint and the O'Hara Complaint. The consolidated case is captioned In re Orthofix Medical Inc. Securities Litigation, Case No. 24-cv-00690 and is pending in the Eastern District of Texas. The Company and the individual defendants moved to dismiss the amended complaint on May 15, 2025. On March 9, 2026, the Court granted defendants' motion to dismiss the plaintiffs' claims under the Exchange Act (but not those under the Securities Act), finding that (i) all but one of the Company's statements at issue were immaterial as a matter of law, and (ii) no statements caused loss. The Court provided the plaintiffs with leave to amend their complaint to address pleading deficiencies, and plaintiffs filed an amended complaint on April 8, 2026.

On October 28, 2024, a derivative shareholder complaint was filed against certain of the Company's current and former officers and directors alleging derivative liability for the allegations made in the two complaints noted above. On December 18, 2024, a second derivative shareholder complaint was filed with the same allegations made in the first derivative shareholder complaint. On March 21, 2025, the two derivative shareholder complaints were consolidated into one case.

The Company disagrees with the legal claims asserted in these complaints and is vigorously defending them. Due in part to the preliminary nature of these three matters, the Company currently cannot reasonably estimate a possible loss, or range of loss, that may arise from the respective complaints.

*Commitments*

As a result of the Merger, the Company became party to agreements with certain distributor partners that provide the Company with an option to purchase, and an option for those partners to require the Company to purchase, the distribution business of those partners at specified future dates. At such time, the Company or distributor may (in certain cases, subject to satisfying certain

------

conditions) submit written notice to the other of its intention to exercise its rights and initiate or require the purchase. Upon receipt of the written notice, the Company and the distributor will work in good faith to consummate the purchase, provided that the distributor meets the required conditions of such purchase option. Under certain of these agreements, the purchase price would be paid in shares of the Company's common stock, whereas for others, the purchase price can be paid in cash or shares, at the Company's option. Based on the closing price of the Company's common stock as of March 31, 2026, assuming the options under all the relevant agreements were exercised, the estimated total number of shares the Company would issue under these agreements was approximately 0.4 million shares for agreements that must be settled in shares of the Company's stock. The Company has received notification from one such distributor, who has notified the Company of its decision to exercise its buyout option. The Company is currently in negotiations with this distributor with respect to the conditions of a potential acquisition, the consummation of which may be deferred to a future date.

*Italian Medical Device Payback (IMDP)*

In 2015, the Italian Parliament introduced rules for entities that supply goods and services to the Italian National Healthcare System. A key provision of the law is a 'payback' measure, requiring medical device companies in Italy to make payments to the Italian government if medical device expenditures exceed regional maximum ceilings. Companies are required to make payments equal to a percentage of expenditures exceeding maximum regional caps.

In the third quarter of 2022, the Italian Ministry of Health provided guidelines to the Italian regions and provinces on seeking payback of expenditure overruns relating to the 2015 through 2018 calendar years. Since receiving the guidelines, several regions and provinces have requested payment from affected medical device companies, including the Company. The Company has taken legal action to dispute the legality of such measures. In July 2024, the Italian Constitutional Court issued two judgments following public hearings on the matter held in May 2024. These judgments (i) declared the payback system itself as constitutionally legitimate and (ii) extended previously communicated reductions in the payback liability for certain fiscal years to all medical device companies, regardless of whether or not they had waived their legal claims on the matter.

The Company accounts for the estimated cost of the IMDP as sales, general, and administrative expense and periodically reassesses the liability based upon current facts and circumstances. As a result, the Company recorded expenses of $0.4 million and $0.3 million for the three months ended March 31, 2026, and 2025, respectively. As of March 31, 2026, the Company has accrued $10.8 million related to the IMDP, which it has classified within other long-term liabilities; however, the actual liability could be higher or lower than the amount accrued once all legal proceedings are resolved and upon further clarification of the IMDP by the Italian authorities.

**8. Accumulated other comprehensive income (loss)**

The components of and changes in accumulated other comprehensive income (loss) were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **(Unaudited, U.S. Dollars, in thousands)** | **Currency<br>Translation<br>Adjustments** | **Neo Medical Convertible Loan** | **Accumulated Other<br>Comprehensive Income (Loss)** |
| Balance at December 31, 2025 | $846 | $(228) | $618 |
| Other comprehensive loss | (476) |  | (476) |
| Income taxes |  |  |  |
| Balance at March 31, 2026 | $370 | $(228) | $142 |

---

**9. Revenue recognition and accounts receivable**

*Revenue Recognition*

The Company has two reporting segments: Global Spine and Global Limb Reconstruction. Within the Global Spine reporting segment, there are two product categories: (i) Therapeutic Solutions (formerly Bone Growth Therapies), and (ii) Spinal Implants, Biologics, and Enabling Technologies.

------

The tables below presents net sales by product category and reporting segment:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **Change** |
| Therapeutic Solutions | $57774 | $55050 | 4.9% |
| Spinal Implants, Biologics, and Enabling Technologies | 106078 | 108786 | -2.5% |
| Global Spine | 163852 | 163836 | 0.0% |
| Global Limb Reconstruction | 32856 | 29810 | 10.2% |
| Net sales | $196708 | $193646 | 1.6% |

---

*Product Sales and Marketing Service Fees*

The table below presents product sales and marketing service fees, which are both components of net sales:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Product sales | $186116 | $181633 |
| Marketing service fees | 10592 | 12013 |
| Net sales | $196708 | $193646 |

---

Marketing service fees are received from MTF Biologics ("MTF") based on total sales of biologic tissues and relate solely to the Biologics product category within the Global Spine reporting segment, whereas product sales primarily consist of the sale of Therapeutic Solutions, Spinal Implants, non-MTF sourced Biologics, Enabling Technologies, and Global Limb Reconstruction products. As MTF is the single supplier for certain allografts in the Company's Biologics portfolio, which are derived from deceased donors for their bone grafts and living donors for their amnion grafts, any event or circumstance that would impact MTF's continued access to donors or the Company's ability to market these tissues may adversely impact the Company's financial results.

*Accounts receivable and related allowances*

The following table provides a detail of changes in the Company's allowance for expected credit losses for the three months ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Allowance for expected credit losses beginning balance | $8308 | $7418 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current period provision for expected credit losses | 719 | 1058 |
| &nbsp;&nbsp;&nbsp;&nbsp;Write-offs charged against the allowance and other | (5) | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of changes in foreign exchange rates | (32) | 137 |
| Allowance for expected credit losses ending balance | $8990 | $8602 |

---

**10. Business segment information** 

The Company's operations are managed through two reporting segments: Global Spine and Global Limb Reconstruction. These reporting segments represent the operating segments for which the President and Chief Executive Officer, who is also the Chief Operating Decision Maker (CODM), reviews financial information and makes resource allocation decisions among businesses. The primary metric used by the CODM in managing the Company is adjusted earnings before interest, tax, depreciation, and amortization ("adjusted EBITDA", a non-GAAP financial measure). Adjusted EBITDA represents earnings before interest income (expense), income taxes, depreciation and amortization, and excludes the impact of share-based compensation and long-term incentive plan expense; gains and losses related to changes in foreign exchange rates; charges related to the Merger and other strategic investments; restructuring costs and impairments related to the discontinuation of the M6 product lines; acquisition-related fair value adjustments; gains and/or losses on investments; litigation and investigation charges; and refunds associated with the Employee Retention Credit established by the Coronavirus Aid, Relief, and Economic Security Act.

Corporate activities are comprised of operating expenses not directly identifiable within the two reporting segments, such as human resources, finance, legal, and information technology functions. The Company neither discretely allocates assets, other than goodwill, to its operating segments nor evaluates the operating segments using discrete asset information.

------

*Global Spine*

The Global Spine reporting segment offers two primary product categories: (i) Therapeutic Solutions and (ii) Spinal Implants, Biologics, and Enabling Technologies.

The Therapeutic Solutions product category manufactures, distributes, and provides support services for market-leading bone growth stimulation devices that enhance bone fusion. These Class II medical devices with special controls are indicated as an adjunctive, noninvasive treatment to improve fusion success rates in the cervical and lumbar spine as well as a therapeutic treatment for non-spinal, appendicular fractures, treating both fresh or nonunion fractures. These products are sold almost exclusively in the U.S., using distributors and direct sales representatives to provide these devices to healthcare providers and their patients.

Spinal Implants, Biologics, and Enabling Technologies is comprised of (i) a broad portfolio of spine fixation implant products used in surgical procedures of the spine, (ii) one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft market segments, and (iii) image-guided surgical solutions to facilitate degenerative, minimally invasive, and complex surgical procedures. Spinal Implants, Biologics, and Enabling Technologies products are sold through a network of distributors and sales representatives to hospitals and healthcare providers on a global basis for Spinal Implants and Enabling Technologies, and primarily within the U.S. for Biologics.

*Global Limb Reconstruction*

The Global Limb Reconstruction reporting segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. This reporting segment specializes in the design, development, and marketing of external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. The Company sells these products worldwide through a global network of distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers.

------

The following table presents adjusted EBITDA, the primary metric used in managing the Company, by reporting segment:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| **(Unaudited, U.S. Dollars, in thousands)** | **Global Spine** | **Global Limb Reconstruction** | **Total** |
| Segment revenues | $163852 | $32856 | $196708 |
| Less: |  |  |  |
| Non-GAAP Cost of sales | 42842 | 14615 | 57457 |
| Non-GAAP Sales, general, and administrative | 98021 | 20201 | 118222 |
| Non-GAAP Research and development | 11397 | 2999 | 14396 |
| Other segment expenses | 259 | 938 | 1197 |
| Add: |  |  |  |
| Non-GAAP Depreciation, amortization, and share-based compensation expense | 9068 | 3228 | 12296 |
| **Segment Adjusted EBITDA** | $20401 | $(2669) | $17732 |
| *Reconciling items:* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate operating expenses |  |  | $8038 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net |  |  | 5664 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization |  |  | 13493 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation and long-term incentive plan expense |  |  | 6638 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange impact |  |  | 900 |
| &nbsp;&nbsp;&nbsp;&nbsp;SeaSpine merger-related costs |  |  | (69) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs and impairments related to M6 product lines |  |  | 253 |
| &nbsp;&nbsp;&nbsp;&nbsp;Strategic investments |  |  | 950 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related fair value adjustments |  |  | 750 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and loss on investments |  |  | (16) |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation and investigation costs |  |  | 2916 |
| &nbsp;&nbsp;&nbsp;&nbsp;Employee Retention Credit |  |  | (951) |
| **Loss before income taxes** |  |  | $(20834) |

---

------

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| **(Unaudited, U.S. Dollars, in thousands)** | **Global Spine** | **Global Limb Reconstruction** | **Total** |
| Segment Revenues | $163836 | $29810 | $193646 |
| Less: |  |  |  |
| Non-GAAP Cost of sales | 44587 | 11871 | 56458 |
| Non-GAAP Sales, general, and administrative | 92538 | 17920 | 110458 |
| Non-GAAP Research and development | 11623 | 2853 | 14476 |
| Other segment expenses (benefits) | 4444 | (175) | 4269 |
| Add: |  |  |  |
| Non-GAAP Depreciation, amortization, and share-based compensation expense | 8872 | 2632 | 11504 |
| **Segment Adjusted EBITDA** | $19516 | $(27) | $19489 |
| *Reconciling items:* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate operating expenses |  |  | $8058 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net |  |  | 4506 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization |  |  | 34431 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation and long-term incentive plan expense |  |  | 6469 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange impact |  |  | (1044) |
| &nbsp;&nbsp;&nbsp;&nbsp;SeaSpine merger-related costs |  |  | 1130 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs and impairments related to M6 product lines |  |  | 12126 |
| &nbsp;&nbsp;&nbsp;&nbsp;Strategic investments |  |  | 3514 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related fair value adjustments |  |  | (610) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and loss on investments |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation and investigation costs |  |  | 3042 |
| &nbsp;&nbsp;&nbsp;&nbsp;Employee Retention Credit |  |  |  |
| **Loss before income taxes** |  |  | $(52133) |

---

The following table presents depreciation, amortization, and impairment by reporting segment:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Global Spine | $10218 | $31902 |
| Global Limb Reconstruction | 2778 | 1936 |
| Corporate | 497 | 593 |
| Total | $13493 | $34431 |

---

------

*Geographical information*

The table below presents net sales by geographic destination for each reporting segment and for the consolidated Company:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| *Global Spine* |  |  |
| U.S. | $152417 | $152703 |
| International | 11435 | 11133 |
| Total Global Spine | 163852 | 163836 |
| *Global Limb Reconstruction* |  |  |
| U.S. | 8911 | 8978 |
| International | 23945 | 20832 |
| Total Global Limb Reconstruction | 32856 | 29810 |
| *Consolidated* |  |  |
| U.S. | 161328 | 161681 |
| International | 35380 | 31965 |
| Net sales | $196708 | $193646 |

---

The following data includes net sales by geographic area:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| U.S. | $161328 | $161681 |
| Italy | 5903 | 5053 |
| France | 2632 | 2625 |
| United Kingdom | 3873 | 3037 |
| Germany | 2170 | 2208 |
| Brazil | 1034 | 1135 |
| Others | 19768 | 17907 |
| Net Sales | $196708 | $193646 |

---

The following data includes property, plant, and equipment by geographic area:

---

| | | |
|:---|:---|:---|
| **(U.S. Dollars, in thousands)** | **March 31,<br>2026** | **December 31,<br>2025** |
|  | (Unaudited) |  |
| U.S. | $111035 | $114483 |
| Italy | 9596 | 9893 |
| Germany | 1165 | 1360 |
| Others | 3531 | 3663 |
| Total | $125327 | $129399 |

---

------

**11. Acquisition-related amortization, impairment, and remeasurement**

Acquisition-related amortization, impairment, and remeasurement consists of (i) amortization and impairment related to intangible assets acquired through business combinations or asset acquisitions and (ii) remeasurement of any related contingent consideration arrangements. Components of acquisition-related amortization, impairment, and remeasurement are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Amortization and impairment of acquired intangibles | $3001 | $18355 |
| Changes in fair value of contingent consideration | 750 | (610) |
| Total | $3751 | $17745 |

---

**12. Share-based compensation**

Components of share-based compensation expense are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Cost of sales | $331 | $461 |
| Sales, general, and administrative | 5858 | 5649 |
| Research and development | 344 | 359 |
| Total | $6533 | $6469 |

---

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** |
| Stock options | $1231 | $869 |
| Market-based stock options | 187 | 646 |
| Time-based restricted stock units | 2885 | 2994 |
| Market-based / performance-based restricted stock units | 1794 | 1420 |
| Stock purchase plan | 436 | 540 |
| Total | $6533 | $6469 |

---

During the three months ended March 31, 2026, and 2025, the Company issued 0.5 million and 0.6 million shares, respectively, of common stock related to stock purchase plan issuances, stock option exercises, and the vesting of restricted stock units.

**13. Income taxes**

Generally, income tax provisions for interim periods are based on an estimated annual income tax rate, adjusted for discrete tax items, with any changes affecting the estimated annual effective tax rate recorded in the interim period in which the change occurs. Due to losses in the Company's U.S., Canadian and Italian operations for which no tax benefit is recognized, the Company determined the estimated annual effective tax rate method would not provide a reliable estimate of the Company's overall annual effective tax rate. As such, the Company has calculated the tax provision using the actual effective rate for the three months ended March 31, 2026. Due to the impact of temporary differences on the current U.S. tax liability for which no deferred tax benefit is recognized, the effective tax rate may vary in future quarters.

For the three months ended March 31, 2026, and 2025, the effective tax rate was (0.4%) and (1.8%), respectively. The primary factors affecting the Company's effective tax rate for the three months ended March 31, 2026, were certain losses for which no tax benefit is recognized and tax amortization on certain acquired intangibles.

------

**14. Earnings per share (EPS)**

For the three months ended March 31, 2026, no adjustments were made to net income for purposes of calculating basic and diluted EPS under the treasury stock method. The following is a reconciliation of the weighted average shares used in diluted EPS computations.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, In thousands)** | **2026** | **2025** |
| Weighted average common shares-basic | 40450 | 39188 |
| Effect of dilutive securities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unexercised stock options and stock purchase plan |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unvested restricted stock units |  |  |
| Weighted average common shares-diluted | 40450 | 39188 |

---

There were 8.3 million and 8.1 million weighted average outstanding options, time-based restricted stock units, performance-based stock units, and market-based stock units not included in the diluted EPS computation for the three months ended March 31, 2026, and 2025, respectively, because either (i) inclusion of these awards was anti-dilutive, or (ii) for performance-based stock units and market-based stock units, all necessary conditions had not been satisfied by the end of the respective period.

**15. Discontinuation of M6 product lines**

In February 2025, the Company announced the discontinuation of its M6-C artificial cervical disc and M6-L artificial lumbar disc product lines (together, the "M6 artificial discs" or "M6 product lines") in order to allocate associated resources and investment to more profitable growth opportunities. Financial results for the Company's M6 product lines continue to be presented within the Company's consolidated statements of operations and comprehensive loss. A summary of impairment charges recognized during the three months ended March 31, 2025, and the associated financial statement lines in which such costs were recognized is shown in the table below. All such changes are included within the Company's Global Spine reporting segment. All related inventory; property, plant, and equipment; and intangible asset balances were fully impaired in the prior year; therefore, there were no further impairments recorded on these assets in the current year.

---

| | | |
|:---|:---|:---|
| **(Unaudited, U.S. Dollars, in thousands)** | **Financial Statement Line Item** | **Three Months Ended March 31, 2025** |
| Inventory reserve charges | Cost of sales | $8703 |
| Impairment of property, plant, and equipment | Operating expenses | 6226 |
| Impairment of developed technology intangible asset | Acquisition-related amortization, impairment, and remeasurement | 14097 |
| Loss on M6 inventories and long-lived assets held for sale | Loss on M6 inventories and long-lived assets held for sale | $29026 |

---

**16. Subsequent Events**

Subsequent to March 31, 2026, the Company finalized certain matters relating to the arbitration proceedings involving the Former Executives, as described above in Note 7, Commitments and Contingencies. On April 22, 2026, the Company made a payment of $14.8 million in satisfaction of the interim arbitration award issued to Keith Valentine on January 26, 2026, including accrued pre-judgment interest at the applicable statutory rate under California law. In addition, on April 15, 2026, the Company reached a settlement with Patrick Keran resolving his pending claims against the Company for a payment of $4.25 million, and on April 22, 2026, the Company entered into a settlement agreement with John Bostjancic resolving his pending claims for a payment of $4.25 million. The Company had previously accrued amounts it believed were probable and estimable related to these matters as of March 31, 2026.

On April 16, 2026, the U.S. Food and Drug Administration published a final order in the Federal Register reclassifying non-invasive bone growth stimulators from Class III to Class II with special controls. The reclassification will become effective on May 18, 2026. For additional discussion of this change, refer to the Company's updated risk factor, included within Part II, Item 1A under the heading *Risk Factors* of this quarterly report.

------

**<u>I</u><u>tem 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>** 

The following discussion and analysis of Orthofix Medical Inc.'s (sometimes referred to as "we," "us" or "our") financial condition and results of operations should be read in conjunction with the discussion under the heading "Forward-Looking Statements" and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.

**Executive Summary**

We are a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, we deliver technology-enabled solutions that support improved clinical outcomes and more efficient care across the continuum. We offer a focused and differentiated portfolio spanning spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System. Learn more at Orthofix.com and follow Orthofix on LinkedIn. Information included on our website is not incorporated into, or otherwise creates a part of, this report.

Notable financial metrics in the first quarter of 2026 and recent achievements include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a constant currency basis, reflecting steady execution during the final stages of distributor transitions, with further improvement expected as productivity increases.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Global Spine Fixation delivered reported net sales growth of 6% and constant currency growth of 6% compared to the prior year period, including U.S. Spine Fixation growth of 4%, driven by enhanced commercial focus, deeper procedural penetration, and continuing benefits from distributor transition initiatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Therapeutic Solutions (formerly Bone Growth Therapies) achieved year-over-year net sales growth of 5%, supported by continued demand across the portfolio and effective commercial execution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Global Limb Reconstruction reported net sales growth of 10% and constant currency growth of 3% compared to the prior year period, reflecting continued demand for core fixation and reconstruction systems.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•First quarter 2026 reported net loss of $(20.9) million and non-GAAP pro forma adjusted EBITDA of $9.7 million, reflecting impacts from geography mix and commercial transitions.

**Results of Operations**

The following table provides certain items in our condensed consolidated statements of operations as a percent of net sales:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited)** | **2026<br>(%)** | **2025<br>(%)** |
| Net sales | 100.0 | 100.0 |
| Cost of sales | 29.1 | 37.2 |
| Gross profit | 70.9 | 62.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales, general, and administrative | 68.5 | 68.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 7.8 | 10.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related amortization, impairment, and remeasurement | 1.9 | 9.2 |
| Operating loss | (7.3) | (25.2) |
| Net loss | (10.6) | (27.4) |

---

------

***Net Sales by Product Category and Reporting Segment***

Our operations are managed through two reporting segments: Global Spine and Global Limb Reconstruction. The following table provides net sales by product category and reporting segment:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in millions)** | **2026** | **2025** | **Change** | **Constant<br>Currency<br>Change** |
| &nbsp;&nbsp;&nbsp;&nbsp;Therapeutic Solutions | $57.8 | $55.1 | 4.9% | 4.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Spinal Implants, Biologics and Enabling Technologies\* | 105.8 | 104.3 | 1.4% | 1.4% |
| Global Spine\* | 163.6 | 159.4 | 2.6% | 2.6% |
| Global Limb Reconstruction | 32.8 | 29.8 | 10.2% | 3.0% |
| **Pro forma net sales\*** | **196.4** | **189.2** | **3.8%** | **2.7%** |
| Impact from discontinuation of M6 product lines | 0.3 | 4.4 | (94.2%) | (94.5%) |
| Reported net sales | $196.7 | $193.6 | 1.6% | 0.4% |

---

\* Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company's pro forma net sales to its reported figures under U.S. GAAP. The Company's reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines.

Global Spine

Global Spine offers the following product categories:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Therapeutic Solutions manufactures, distributes, sells, and provides support services for market-leading devices used adjunctively in high-risk spinal fusion procedures and treats both nonunion and acute fractures in the orthopedic space. Therapeutic Solutions uses distributors and a direct sales channel to sell its devices and provide associated support services to hospitals, healthcare providers, and patients in the U.S.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Spinal Implants, Biologics, and Enabling Technologies is comprised of a broad portfolio of spine fixation implant products used in surgical procedures of the spine, one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft market segments and image-guided surgical solutions to facilitate degenerative, minimally invasive, and complex surgical procedures. Spinal Implants, Biologics, and Enabling Technologies products are sold through a network of distributors and sales representatives to hospitals and healthcare providers on a global basis for Spinal Implants and Enabling Technologies, and primarily within the U.S. for Biologics.

*Three months ended March 31, 2026 compared to 2025* 

Net sales of $163.9 million, flat compared to the prior year period

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Therapeutic Solutions net sales increased $2.7 million, or 4.9%, largely driven by (i) favorable changes in average sales prices and (ii) increases in gross order volumes from our continued investment in our direct sales channels for both the spine and fracture markets

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Spinal Implants, Biologics, and Enabling Technologies net sales, excluding sales from the M6 product lines, increased $1.5 million, or 1.4%, primarily due to increased sales growth from new and existing high-volume distributor partners within Spine Fixation, which saw growth in its cervical, thoracolumbar, and interbody franchises; growth in these areas was partially offset by a decline in Biologics and Enabling Technologies. The decrease in Enabling Technologies was due to the timing of revenue in the prior year from completed contracts under the Voyager Earnout program.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Net sales from the M6 product lines decreased $4.2 million, or 94.2%, as a result of the discontinuation of the product lines in 2025 to focus resources and investments in more profitable growth opportunities

Global Limb Reconstruction

Global Limb Reconstruction offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. Global Limb Reconstruction sells its products through a global network of distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers.

------

*Three months ended March 31, 2026 compared to 2025*

Net sales of $32.8 million, an increase of $3.0 million or 10.2% on a reported basis and 3.0% on a constant currency basis

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•U.S. net sales decline of $0.1 million, or 0.8%, largely due to timing of large capital sales orders, partially offset by growth from new products launched in the past three years

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•International sales increase of $3.1 million, or 4.6% on a constant currency basis, primarily driven by sales of new products launched in the past three years and partially offset by large tender orders in the prior year

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Net sales increase of $2.2 million due to movement in foreign currency exchange rates, which had a favorable impact during the quarter

***Gross Profit***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **% Change** |
| Net sales | $196708 | $193646 | 1.6% |
| Cost of sales | 57162 | 72027 | (20.6%) |
| Gross profit | $139546 | $121619 | 14.7% |
| Gross margin | 70.9% | 62.8% | 8.1% |

---

*Three months ended March 31, 2026 compared to 2025*

Gross profit increased $17.9 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Increase in gross profit of $12.4 million resulting from significant inventory reserve expenses recorded in the first quarter of 2025, primarily attributable to the discontinuation of the M6 product lines in order to focus resources and investments on more profitable growth opportunities

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Increase in gross profit also driven by reduced headcount, overhead costs, and depreciation, resulting from the discontinuation of the M6 product lines

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•These changes were also partially offset by certain changes in geographical mix of net sales

***Sales, General, and Administrative Expense***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **% Change** |
| Sales, general, and administrative | $134911 | $132981 | 1.5% |
| As a percentage of net sales | 68.6% | 68.7% | (0.1%) |

---

*Three months ended March 31, 2026 compared to 2025* 

Sales, general, and administrative expense increased $1.9 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Increase of $2.9 million primarily driven by increased compensation and benefit costs, including variable compensation and share-based compensation expense

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Increase of $0.7 million in professional fees and insurance costs, mostly pertaining to an increase in accrued settlement fees and costs

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Partially offset by a decrease of $2.3 million in depreciation expense, mostly as a result of impairments incurred in the prior year as a result of the discontinuation of the M6 product lines

------

***Research and Development Expense***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **% Change** |
| Research and development | $15320 | $19766 | (22.5%) |
| As a percentage of net sales | 7.8% | 10.2% | (2.4%) |

---

*Three months ended March 31, 2026 compared to 2025* 

Research and development expense decreased $4.4 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Decrease of $4.8 million related to impairments associated with the discontinuation of the M6 product lines and other organizational restructuring activities that occurred in 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Partially offset by an increase of $0.4 million in clinical studies and product development costs

***Acquisition-related Amortization, Impairment, and Remeasurement***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **% Change** |
| Acquisition-related amortization, impairment, and remeasurement | $3751 | $17745 | (78.9%) |
| As a percentage of net sales | 1.9% | 9.2% | (7.3%) |

---

Acquisition-related amortization, impairment, and remeasurement consists of (i) amortization and impairment related to intangible assets acquired through business combinations or asset acquisitions and (ii) remeasurement of related contingent consideration arrangements, which are recognized immediately upon acquisition.

*Three months ended March 31, 2026 compared to 2025*

Acquisition-related amortization, impairment, and remeasurement decreased $14.0 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Decrease of $15.4 million in amortization expense primarily associated with the impairment of certain acquired intangible assets as a result of the discontinuation of the M6 product lines

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Partially offset by an increase of $1.4 million associated with the remeasurement of a contingent consideration obligation with Lattus Spine LLC assumed in the merger with SeaSpine Holdings Corporation (the "Merger")

***Non-operating Income and Expense*** 

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **% Change** |
| Interest expense, net | $(5664) | $(4506) | 25.7% |
| Other income (expense), net | (734) | 1246 | (158.9%) |

---

*Three months ended March 31, 2026 compared to 2025* 

Interest expense, net increased $1.2 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Unfavorable change of $1.4 million attributable to an increase in interest expense following the funding of the $65.0 million Term B Loan in January 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Partially offset by a favorable change of $0.2 million resulting from interest earned on certain Employee Retention Credit refunds received in the first quarter of 2026

Other income (expense), net decreased $2.0 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Unfavorable change of $2.0 million associated with foreign currency exchange rates, as we recorded a non-cash remeasurement loss of $0.9 million in first quarter of 2026 compared to a gain of $1.1 million in the first quarter of 2025

------

***Income Taxes***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **% Change** |
| Income tax expense | $74 | $961 | (92.3%) |
| Effective tax rate | (0.4%) | (1.8%) | 1.4% |

---

*Three months ended March 31, 2026 compared to 2025* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The decrease in income tax expense compared to the prior year period was primarily related to tax benefits on certain international operations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The primary factor affecting our tax expense for the first quarter of 2026 was tax amortization on certain acquired intangibles

**Liquidity and Capital Resources**

Cash, cash equivalents, and restricted cash at March 31, 2026, totaled $120.9 million compared to $85.1 million at December 31, 2025. The following table presents the net change in cash, cash equivalents, and restricted cash for the three months ended March 31, 2026, and 2025, respectively:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **Change** |
| Net cash used in operating activities | $(17610) | $(18391) | $781 |
| Net cash used in investing activities | (10515) | (6736) | (3779) |
| Net cash provided by (used in) financing activities | 63970 | (651) | 64621 |
| Effect of exchange rate changes on cash | (90) | 493 | (583) |
| Net change in cash and cash equivalents | $35755 | $(25285) | $61040 |

---

The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **(Unaudited, U.S. Dollars, in thousands)** | **2026** | **2025** | **Change** |
| Net cash used in operating activities | $(17610) | $(18391) | $781 |
| Capital expenditures | (10661) | (6736) | (3925) |
| Free cash flow | $(28271) | $(25127) | $(3144) |

---

***Operating Activities***

Cash flows used in operating activities decreased $0.8 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Decrease in net loss of $32.2 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Decrease of $31.3 million associated with non-cash gains and losses, such as depreciation, amortization, and impairments, inventory reserve expenses, remeasurement of contingent consideration obligations, changes in the valuation of investment securities, and share-based compensation expense

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Decrease of $0.1 million relating to changes in working capital accounts, primarily attributable to changes in accounts receivable, inventories, and other current liabilities

Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 63 days at March 31, 2026, compared to 61 days at March 31, 2025 (calculated using first quarter net sales and ending accounts receivable). Inventory turns decreased to 1.4 times as of March 31, 2026 compared to 1.5 times as of March 31, 2025 (calculated using trailing twelve-month cost of goods sold and ending net inventories).

------

***Investing Activities***

Cash flows used in investing activities increased $3.8 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Increase in spend of $3.9 million in capital expenditures and partially offset by decrease of $0.1 million in other investing activities

***Financing Activities***

Cash flows from financing activities increased $64.6 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Increase of $64.0 million associated with net borrowing activities related to our credit facilities in the first quarter of 2026 compared to the prior year period

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Favorable change of $0.5 million in debt issuance costs associated with our credit facilities in the first quarter 2026 compared to the prior year period

*Credit Facilities*

On November 7, 2024, we entered into a $275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including Oxford, K2 HealthVentures LLC, and HSBC Ventures USA Inc. Certain of our foreign subsidiaries joined the Credit Agreement as guarantors shortly after the signing date. The Credit Agreement provides for a $160.0 million senior secured term loan (the "Initial Term Loan") and a $65.0 million senior secured delayed draw term loan facility (the "Term B Loan") which Term B Loan was fully funded on January 15, 2026. In addition, at Oxford's discretion, an additional $50.0 million of draw capacity is available through January 1, 2029 (the "Term C Loan" and, together with the Term B Loan, the "Delayed Draw Term Loans" and collectively with the Initial Term Loan, the "Credit Facilities").

The Initial Term Loan and Delayed Draw Term Loans, to the extent ultimately drawn, will each mature in November 2029, following an interest-only payment period ending December 2028, and monthly amortization of principal and accrued interest between January 2029 and November 2029.

The Initial Term Loan and Delayed Draw Term Loans, to the extent ultimately drawn, are subject to, among other conditions, our continued compliance with a pro-forma total debt-to-EBITDA leverage ratio of less than 4.0x. EBITDA is a non-GAAP financial measure which represents earnings before interest income (expense), income taxes, depreciation, amortization, and other negotiated addbacks and adjustments.

The Credit Agreement contains financial covenants requiring us to maintain a minimum level of liquidity at all times and to maintain a maximum total debt-to-EBITDA leverage ratio (measured on a quarterly basis) during the term of the facility. As of March 31, 2026, we were in compliance with all required financial covenants.

As of March 31, 2026, we had $225.0 million of outstanding borrowings under the Credit Agreement related to the Initial Term Loan and the Term B Loan. We have not made any borrowings under the Term C Loan as of March 31, 2026.

As of March 31, 2026, we had no borrowings on our available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($6.4 million).

***Other***

For information regarding contingencies, see Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.

*Lattus Spine LLC ("Lattus") Contingent Consideration*

Under the terms of a contingent consideration obligation in a purchase agreement assumed in the Merger, we may be required to make installment payments at certain dates based on future net sales of certain products (the "Lateral Products"). We made payments of $6.3 million under this arrangement during the year ended December 31, 2025. The estimated fair value of the remaining contingent consideration arrangement as of March 31, 2026, was $8.7 million. The actual amount ultimately paid could be higher or lower than the estimated fair value of the contingent consideration. As of March 31, 2026, we classified the remaining contingent consideration liability of $4.7 million and $4.0 million within other current liabilities and other long-term liabilities,

------

respectively. For additional discussion of this matter, see Note 6 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

***Off-balance Sheet Arrangements***

As of March 31, 2026, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.

***Contractual Obligations***

There have been no material changes in any of our material contractual obligations as disclosed in our Form 10-K for the year ended December 31, 2025.

***Critical Accounting Estimates***

Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are described in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no significant changes to our critical accounting estimates during the quarter covered by this report.

***Recently Issued Accounting Pronouncements***

See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued or adopted accounting pronouncements.

**Non-GAAP Financial Measures**

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP financial measures used to supplement information regarding the performance and underlying trends of our business operations to facilitate comparisons to historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their U.S. GAAP results with non-GAAP financial measures.

The non-GAAP financial measures used in this filing may have limitations as analytical tools and should not be considered in isolation or as a replacement for U.S. GAAP financial measures. Some limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.

*Constant Currency*

Constant currency is calculated by using foreign currency rates from the comparable, prior year period to present net sales at comparable rates. Constant currency can be presented for numerous U.S. GAAP measures but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

*Free Cash Flow*

Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Management uses free cash flow as an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

**<u>I</u><u>tem 3. Quantitative and Qualitative Disclosures About Market Risk</u>** 

There have been no material changes to our market risks as disclosed in our Form 10-K for the year ended December 31, 2025.

------

**<u>I</u><u>tem 4. Controls and Procedures</u>**

**Evaluation of Disclosure Controls and Procedures** 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026.

**Changes in Internal Control over Financial Reporting** 

There was no change in our internal control over financial reporting that occurred during the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

**PART II. OTHER INFORMATION** 

**<u>Item 1. Legal</u> <u>Proceedings</u>** 

For information regarding legal proceedings, see Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein, which is incorporated by reference into this Part II, Item 1.

**<u>Item 1A. Ris</u><u>k Factors</u>**

*The U.S. Food and Drug Administration's ("FDA") reclassification of bone growth stimulator devices from Class III to Class II may increase competition and adversely affect our future sales.*

We offer the market-leading bone growth stimulation platform and are the only company to provide both pulsed electromagnetic field (PEMF) and low-intensity pulsed ultrasound (LIPUS) bone healing solutions. Historically, our bone growth therapy products were regulated by the FDA as Class III medical devices, subject to the FDA's rigorous premarket approval (PMA) requirements.

The FDA has reclassified bone growth stimulator devices from Class III to Class II, subject to "special controls." These special controls include requirements for clinical data, specific non-clinical performance and biocompatibility data, and labeling, in addition to the Class II requirement that new devices demonstrate substantial equivalence to a legally marketed predicate device. While these controls are intended to provide reasonable assurance of safety and effectiveness, the Class II regulatory pathway is generally less onerous, time-consuming, and costly than the PMA process applicable to Class III devices.

As a result of this reclassification, competitors may be able to enter the market more readily by obtaining FDA clearance for bone growth stimulator devices that are substantially equivalent to existing products. Increased market entry could lead to heightened competition, pricing pressure, and greater marketing and promotional activity by competitors, which may reduce demand for our products or erode our market share.

Although we believe our clinical data, dual-technology platform, and brand recognition differentiate our products, we may be required to increase investments in research and development, clinical studies, sales, marketing, and post-market surveillance to maintain our competitive position. Any such increased costs, or a failure to effectively compete in a more crowded market, could adversely affect our revenues, margins, and results of operations.

Other than as disclosed above, there have been no material changes from the risk factors disclosed in "Part I, Item 1A. Risk Factors" in our Form 10-K for the year ended December 31, 2025.

**<u>Item 2. Unregistered Sales of Equit</u><u>y Securities and Use of Proceeds</u>**

We have not made any repurchases of our common stock during the first quarter of 2026.

**<u>Item 3. Defaults Upo</u><u>n Senior Securities</u>**

Not applicable.

**<u>Item 4. Mine Saf</u><u>ety Disclosures</u>**

Not applicable.

**<u>Item 5. Other</u> <u>Information</u>**

During the last fiscal quarter, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any "non-Rule 10b5-1 trading arrangement."

**<u>Item 6. E</u><u>xhibits</u>**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;31.1\* | [<u>Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.</u>](ofix-ex31_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;31.2\* | [<u>Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.</u>](ofix-ex31_2.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;32.1# | [<u>Section 1350 Certifications of each of the Chief Executive Officer and Chief Financial Officer.</u>](ofix-ex32_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;10.1 | [<u>Sixth Amendment to the Lease Agreement between AR Industrial No. 1 Ltd. and Orthofix US LLC (f/k/a Orthofix Inc.) dated January 15, 2026 (Filed as Exhibit 10.10 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and incorporated herein by reference).</u>](https://www.sec.gov/Archives/edgar/data/884624/000119312526065189/ofix-ex10_10.htm) |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;10.2\* | [<u>2026 Long-Term Performance Award Grant Agreement for 2012 LTIP.</u>](ofix-ex10_2.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;101.INS\* | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| &nbsp;&nbsp;&nbsp;&nbsp;101.SCH\* | Inline XBRL Taxonomy Extension Schema Document. |
| &nbsp;&nbsp;&nbsp;&nbsp;101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| &nbsp;&nbsp;&nbsp;&nbsp;101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| &nbsp;&nbsp;&nbsp;&nbsp;101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| &nbsp;&nbsp;&nbsp;&nbsp;101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| &nbsp;&nbsp;&nbsp;&nbsp;104\* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |

---

\* Filed herewith.

# Furnished herewith.

------

**SIGNATURES** 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | ORTHOFIX MEDICAL INC. | ORTHOFIX MEDICAL INC. |
| &nbsp;&nbsp;&nbsp;&nbsp;Date: May 5, 2026 | By: | /s/ MASSIMO CALAFIORE |
|  | Name: | Massimo Calafiore |
|  | Title: | President and Chief Executive Officer |
| &nbsp;&nbsp;&nbsp;&nbsp;Date: May 5, 2026 | By: | /s/ JULIE ANDREWS |
|  | Name: | Julie Andrews |
|  | Title: | Chief Financial Officer |

---

------

## Exhibit 10.2

![gfx50190239_0.jpg](gfx50190239_0.jpg)

Exhibit 10.2

**ORTHOFIX MEDICAL INC.**

**AMENDED AND RESTATED 2012 LONG-TERM INCENTIVE PLAN**

**Long-Term Performance Award Grant Agreement**

**<br>COVER SHEET**

Orthofix Medical Inc., a Delaware corporation (the "***Company***"), hereby grants to the Award Recipient named below, on the Grant Date set forth below, a long-term Performance Award with respect to the target cash amount described below (the "***Target Award Amount***") under the Plan, subject to the vesting schedule and terms and conditions set forth below (the "***Award***"). Additional terms and conditions of the Award are set forth on this cover sheet, in the attached Long-Term Performance Award Grant Agreement (together, the "***Agreement***"), and in the Company's Amended and Restated 2012 Long-Term Incentive Plan (as amended from time to time, the "***Plan***"). Capitalized terms used and not otherwise defined herein shall have the meanings attributed thereto in the Plan.

---

| | |
|:---|:---|
| &nbsp;&nbsp; <br>**Grant Date:** | &nbsp;&nbsp; <br>[ ] |
| &nbsp;&nbsp; <br>**Name of Award Recipient:** | &nbsp;&nbsp; <br>[ ] |
| &nbsp;&nbsp; <br>**Employee ID Number:** | &nbsp;&nbsp; <br>[ ] |
| &nbsp;&nbsp; <br>**Target Award Amount:** | &nbsp;&nbsp;<br>$[ ], subject to adjustment as provided by the Agreement. |

---

**Payment:** The actual amount of any payment made pursuant to this Award shall range from 0% - 200% of the Target Award Amount, to be determined pursuant to Section 2 of the Agreement. The maximum payment that may be made to the Award Recipient is equal to 200% of the Target Award Amount.

**Vesting Date:** Subject to the terms and conditions of the Agreement (including, without limitation, conditions requiring continued Service with the Company through the applicable date), this Award vests on March 3, 2029 (the "***Scheduled Vesting Date***").

***You agree to all of the terms and conditions described in this Agreement and in the Plan, unless you deliver a notice in writing within thirty (30) days of receipt of this Agreement to the Company stating that you do not accept the terms and conditions described in this Agreement and in the Plan. You acknowledge that you have carefully reviewed the Plan and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent.***

*<u>Attachment</u><br>This is not a stock certificate or a negotiable instrument.*

MACROBUTTON DocID \\4131-8922-2758 v4

------

**ORTHOFIX MEDICAL INC.**

**AMENDED AND RESTATED 2012 LONG-TERM INCENTIVE PLAN**

**Long-Term Performance Award Grant Agreement**

**Attachment**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Definitions</u>. For purposes of this Agreement, the following capitalized words shall have the meanings set forth below.

"***Adjusted EBITDA Margin Performance Multiplier***" means the percentage calculated based on the respective Adjusted EBITDA Margin for the applicable fiscal year ending December 31<sup>st</sup> set forth in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Adjusted EBITDA Margin** | **Adjusted EBITDA Margin** | **Adjusted EBITDA Margin** | **Adjusted EBITDA Margin** | **Adjusted EBITDA Margin Performance Multiplier** |
|  | **2026 Fiscal Year** | **2027 Fiscal Year** | **2028 Fiscal Year** |  |
| Threshold | 9.00% | 10.50% | 12.00% | 0.0% |
|  | 10.25% | 11.75% | 13.50% | 50.0% |
| **Target** | **11.50%** | **13.00%** | **15.00%** | **100.0%** |
|  | 12.25% | 14.00% | 16.00% | 150.0% |
| Maximum | 13.00% | 15.00% | 17.00% | 200.0% |

---

<br>If the Company achieves Adjusted EBITDA Margin for an applicable fiscal year that falls between the foregoing levels, the Adjusted EBITDA Margin Performance Multiplier with respect to such fiscal year will be determined by linear interpolation between the applicable levels noted above, up to a maximum funding of 200% of target with respect to such fiscal year's Adjusted EBITDA Margin component. When calculating Adjusted EBITDA Margin for any applicable financial year, the Committee shall have the authority to make appropriate adjustments to Adjusted EBITDA Margin to account for changes in accounting standards and adopted changes in accounting principles. In each case, the Adjusted EBITDA Margin shall be rounded up to the nearest hundredth of a percent and the Adjusted EBITDA Margin Performance Multiplier shall be rounded up to the nearest tenth of a percent.

"***Baseline Revenue***" means Revenue for the fiscal year ending December 31, 2025.

"***Cause***" shall mean (i) if the Award Recipient is party to a Change in Control and Severance Agreement that defines "Cause," the definition of "Cause" contained in such Change in Control and Severance Agreement, or (ii) if the Award Recipient is not party to a Change in Control and Severance Agreement that defines "Cause," the definition of "Cause" contained in the Plan.

"***Change in Control***" shall mean (i) if the Award Recipient is party to a Change in Control and Severance Agreement that defines "Change in Control," the definition of "Change in Control" contained in such Change in Control and Severance Agreement, or (ii) if the Award Recipient is not party to a Change in Control and

MACROBUTTON DocID \\4131-8922-2758 v4

------

Severance Agreement that defines "Change in Control," the definition of "Corporate Transaction" contained in the Plan.

"***Change in Control and Severance Agreement***" shall mean a written change in control and severance agreement between the Award Recipient and the Company.

"***Divested or Discontinued***" shall mean a divestiture or discontinuation of a business or product line that triggers discontinued operations accounting treatment under GAAP or is otherwise determined and certified by the Committee as being a disposition representing a significant or strategic disposition.

"***Excluded Items***" shall mean (i) the effect of currency fluctuations that have occurred since the completion of the fiscal year ended December 31, 2025, and (ii) the effect of any product tariffs or changes in law or regulation that are implemented after the completion of the fiscal year ended December 31, 2025 and determined and certified by the Committee as being excludable.

"***Good Reason***" shall mean (i) if the Award Recipient is party to a Change in Control and Severance Agreement that defines "Good Reason," the definition of "Good Reason" contained in such Change in Control and Severance Agreement, or (ii) if the Award Recipient is not party to a Change in Control and Severance Agreement that defines "Good Reason," the Award Recipient voluntarily terminating his or her employment, following a Corporate Transaction, after the occurrence of any of the following circumstances (in each case, after notice by the Award Recipient to employer of the circumstance, and failure by the employer to cure and eliminate such circumstance within 15 calendar days of such notice): (x) a requirement that the Award Recipient work principally from a location that is more than fifty (50) miles from his or her principal place of employment immediately prior to such Corporate Transaction, or (y) a ten percent or greater reduction in the Award Recipient's Total Compensation from the amount of such Total Compensation immediately prior to such Corporate Transaction.

"***Pro Rata Performance Multiplier***" means (i) to the extent such termination occurs between the date that is six (6) months following the Grant Date and December 31, 2026, then the sum of (A) the Adjusted EBITDA Margin Performance Multiplier applicable to the 2026 Adjusted EBITDA Margin multiplied by a weighting of 70% and (B) the Revenue Growth Performance Multiplier applicable to the 2026 Revenue Growth multiplied by a weighting of 30%, (ii) to the extent such termination occurs between January 1, 2027 and December 31, 2027, then the sum of (A) the Adjusted EBITDA Margin Performance Multiplier applicable to the 2026 Adjusted EBITDA Margin multiplied by a weighting of 35%, (B) the Adjusted EBITDA Margin Performance Multiplier applicable to the 2027 Adjusted EBITDA Margin multiplied by a weighting of 35%, (C) the Revenue Growth Performance Multiplier applicable to the 2026 Revenue Growth multiplied by a weighting of 15%, and (D) the Revenue Growth Performance Multiplier applicable to the 2027 Revenue Growth multiplied by a weighting of 15%, and (iii) to the extent such termination occurs between January 1, 2028, and March 2, 2029, then the same aggregate multiplier used to compute the Aggregate Award Payout (inclusive of the Revenue Growth Component Cap).

"***Revenue***" means the GAAP net sales of the Company and its subsidiaries on a consolidated basis as publicly reported by the Company in its annual report on Form 10-K for a completed fiscal year, adjusted to exclude the Excluded Items.

"***Revenue Growth***" means the amount of growth, measured as a percentage, in the Company's Revenue for a completed fiscal year as compared to a prior completed fiscal year; provided, however, that when determining Revenue Growth, the (i) the Revenue impact of any business or product lines that have been Divested or Discontinued as of the end of the applicable completed fiscal year ("***Divestitures/Discontinuations***") shall be excluded with respect to both measurement years (as if such Divestitures/Discontinuations had occurred as of the beginning of the earlier fiscal year being measured), and (ii) the Revenue impact of any acquisition transaction (an "***Acquisition Transaction***") shall be treated as follows: (A) for the first four fiscal quarters following the closing of an Acquisition Transaction, the Revenue impact of the Acquisition Transaction shall be excluded from the calculation of Revenue Growth (except for any Acquisition Transactions that collectively have less than $25.0 million in annualized run rate Revenue, which shall be deemed *de minimis* and not excluded up to such aggregate $25.0 million limit), and (B) commencing with the fifth fiscal quarter following the closing of an Acquisition Transaction and thereafter, the Revenue impact of any Acquisition Transaction shall be included in the Revenue for all financial periods (i.e., the applicable completed fiscal year and the earlier fiscal year being measured).

MACROBUTTON DocID \\4131-8922-2758 v4

------

"***Revenue Growth Performance Multiplier***" means the percentage calculated based on the respective Revenue Growth set forth in the table below:

---

| | | |
|:---|:---|:---|
| **Revenue Growth** | **Revenue Growth** | **Revenue Performance Multiplier** |
| Threshold  | 4.00% | 0.0% |
|  | 5.50% | 50.0% |
| **Target**  | **7.00%** | **100.0%** |
|  | 8.50% | 150.0% |
| Maximum  | 10.00% | 200.0% |

---

<br>If the Company achieves Revenue Growth for an applicable fiscal year that falls between the foregoing levels, the Revenue Performance Multiplier with respect to such fiscal year will be determined by linear interpolation between the applicable levels noted above, up to a maximum funding of 200% of target with respect to such fiscal year's Revenue Growth component. When calculating Revenue Growth relative to any applicable financial years, the Committee shall have the authority to make appropriate adjustments to Revenue to account for changes in accounting policies as it relates to revenue recognition and/or changes in accounting standards and adopted changes in accounting principles issued by accounting bodies to the extent necessary or appropriate to maintain consistency and comparability between periods. In each case, the Revenue Growth shall be rounded up to the nearest hundredth of a percent and the Revenue Performance Multiplier shall be rounded up to the nearest tenth of a percent.

"***Total Compensation***" shall mean the aggregate of base salary, target bonus opportunity, employee benefits (retirement plan, welfare plans, and fringe benefits), and grant date fair value of equity-based compensation, but excluding for the avoidance of doubt any reductions caused by the failure to achieve performance targets) taken as a whole.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>The Award; Performance Adjustment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Grant of Award</u>. On the Grant Date, the Award Recipient shall receive, subject to the provisions of this Agreement (including, without limitation, provisions related to vesting and forfeiture thereof), the Award, subject to determination as set forth in Section 2(b), Section 2(c) or Section 2(d) of this Agreement, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Performance Adjustment/Payment Determination</u>. Subject to satisfaction of the vesting requirements of Section 2(e) of this Agreement, and except as otherwise specified in Section 2(c) or Section 2(d) of this Agreement, the Award shall vest and become payable on the date specified in Section 2(f) of this Agreement, and the amount payable in settlement of the Award shall be calculated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)*2026 Adjusted EBITDA Margin Component (23 1/3% of Total)*. Following the completion of the Company's annual financial statements for the fiscal year ending December 31, 2026, the Company will calculate Adjusted EBITDA Margin for the fiscal year ending December 31, 2026 ("***2026 Adjusted EBITDA Margin***"). To the extent the 2026 Adjusted EBITDA Margin is equal to or greater than 9.00%, the amount payable pursuant to the "***2026 Adjusted EBITDA Margin Component***" will be equal to the Target Award Amount, multiplied by the Adjusted EBITDA Margin Performance Multiplier associated with such 2026 Adjusted EBITDA Margin, and further multiplied by a weighting of 23 1/3%. If such 2026 Adjusted EBITDA Margin is less than 9.00% (including if it is negative), the 2026 Adjusted EBITDA Margin Component shall be zero.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)*2027 Adjusted EBITDA Margin Component (23 1/3% of Total)*. Following the completion of the Company's annual financial statements for the fiscal year ending December 31, 2027, the Company will calculate Adjusted EBITDA Margin for the fiscal year ending December 31, 2027 ("***2027 Adjusted EBITDA Margin***"). To the extent the 2027 Adjusted EBITDA Margin is equal to or greater than 10.50%, the amount payable pursuant to the "***2027 Adjusted EBITDA Margin Component***" will be equal to the Target Award Amount, multiplied by the Adjusted EBITDA Margin Performance Multiplier associated with such 2027 Adjusted

MACROBUTTON DocID \\4131-8922-2758 v4

------

EBITDA Margin, and further multiplied by a weighting of 23 1/3%r. If such 2027 Adjusted EBITDA Margin is less than 10.50% (including if it is negative), the 2027 Adjusted EBITDA Margin Component shall be zero.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)*2028 Adjusted EBITDA Margin Component (23 1/3% of Total)*. Following the completion of the Company's annual financial statements for the fiscal year ending December 31, 2028, the Company will calculate Adjusted EBITDA Margin for the fiscal year ending December 31, 2028 ("***2028 Adjusted EBITDA Margin***"). To the extent the 2028 Adjusted EBITDA Margin is equal to or greater than 12.00%, the amount payable pursuant to the "***2028 Adjusted EBITDA Margin Component***" will be equal to the Target Award Amount, multiplied by the Adjusted EBITDA Margin Performance Multiplier associated with such 2028 Adjusted EBITDA Margin, and further multiplied by a weighting of 23 1/3%. If such 2028 Adjusted EBITDA Margin is less than 12.00% (including if it is negative), the 2028 Adjusted EBITDA Margin Component shall be zero.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)*2026 Revenue Growth Component (10% of Total)*. Following the completion of the Company's annual financial statements for the fiscal year ending December 31, 2026, the Company will compare Revenue for the fiscal year ending December 31, 2026 ("***2026 Revenue***") against the Baseline Revenue. To the extent the 2026 Revenue growth is equal to or greater than 4.00% of the Baseline Revenue, the amount payable pursuant to the "***2026 Revenue Growth Component***" will be equal to the Target Award Amount, multiplied by the Revenue Performance Multiplier associated with such Revenue Growth, and further multiplied by a weighting of 10%. If such 2026 Revenue growth is less than 4.00% (including if it is negative), the 2026 Revenue Growth Component shall be zero.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)*2027 Revenue Growth Component (10% of Total)*. Following the completion of the Company's annual financial statements for the fiscal year ending December 31, 2027, the Company will compare Revenue for the fiscal year ending December 31, 2027 ("***2027 Revenue***") against the 2026 Revenue. To the extent the 2027 Revenue growth is equal to or greater than 4.00% of the 2026 Revenue, the amount payable pursuant to the "***2027 Revenue Growth Component***" will be equal to the Target Award Amount multiplied by the Revenue Performance Multiplier associated with such Revenue Growth, and further multiplied by a weighting of 10%. If such 2027 Revenue growth is less than 4.00% (including if it is negative), the 2027 Revenue Growth Component shall be zero.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)*2028 Revenue Growth Component (10% of Total)*. Following the completion of the Company's annual financial statements for the fiscal year ending December 31, 2028, the Company will compare Revenue for the fiscal year ending December 31, 2028 ("***2028 Revenue***") against the 2027 Revenue. To the extent the 2028 Revenue growth is equal to or greater than 4.00% of the 2027 Revenue, the amount payable pursuant to the "***2028 Revenue Growth Component***" will be equal to the Target Award Amount multiplied by the Revenue Performance Multiplier associated with such Revenue Growth, and further multiplied by a weighting of 10%. If such 2028 Revenue growth is less than 4.00% zero (including if it is negative), the 2028 Revenue Growth Component shall be zero.

For purposes hereof, the "***Aggregate Award Payout***" shall mean the amount equal to the sum of the 2026 Adjusted EBITDA Margin Component, the 2027 Adjusted EBITDA Margin Component, the 2028 Adjusted EBITDA Margin Component, the 2026 Revenue Growth Component, the 2027 Revenue Growth Component and the 2028 Revenue Growth Component; provided, however, that if the Revenue Growth between the 2028 Revenue and the Baseline Revenue is not positive, the portion of the Aggregate Award Payout attributable to the sum of the 2026 Revenue Growth Component, the 2027 Revenue Growth Component and the 2028 Revenue Growth Component shall be capped so as not to exceed 30% (i.e., the aggregate target amount of such three components) of the Target Award Amount (the "***Revenue Growth Component Cap***").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Death or Disability</u>. Notwithstanding Section 2(b), upon the Award Recipient's termination of Service prior to a Change in Control due to death or Disability, the amount payable pursuant to this Award shall be the Target Award Amount (i.e., the aggregate target amount), without regard to the Adjusted EBITDA Margin Performance Multiplier or the Revenue Net Sales Performance Multiplier for any of the fiscal years ending December 31, 2026, 2027 or 2028.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Occurrence of Change in Control</u>. Notwithstanding Section 2(b), in the event of a Change in Control, the amount payable pursuant to this Award shall be the greater of (i) the Target Award Amount,

MACROBUTTON DocID \\4131-8922-2758 v4

------

without regard to the Adjusted EBITDA Margin Performance Multiplier or the Revenue Performance Multiplier and (ii) the Aggregate Award Payout, without regard to the Revenue Growth Component Cap; provided, however, that in the event that one or more of the 2026 Adjusted EBITDA Margin Component, the 2027 Adjusted EBITDA Margin Component, the 2028 Adjusted EBITDA Margin Component, the 2026 Revenue Growth Component, the 2027 Revenue Growth Component and the 2028 Revenue Growth Component has not yet been determined because the associated Revenue Growth Performance Multiplier or Adjusted EBITDA Margin Performance Multiplier, as applicable, has not yet been calculated, the Aggregate Award Payout for purposes of this Section 2(d) shall be equal to the sum of all such components that have been determined plus, for any components that have not yet been determined, the amount of any such component calculated using a Revenue Growth Performance Multiplier or Adjusted EBITDA Margin Performance Multiplier, as applicable, of 100%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Vesting; Forfeiture</u>. Provided that the Award Recipient's Service has not terminated prior to the applicable date, this Award shall become vested upon the earliest date to occur of the following (the "***Vesting Date***"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the Scheduled Vesting Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)the Award Recipient's death;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)termination of the Award Recipient's Service due to Disability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)immediately before any Change in Control in which the surviving, continuing, successor, or purchasing corporation or other business entity or parent thereof, as the case may be, elects not to assume or substitute for this Award; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)termination of the Award Recipient's Service by the Company (or the Company's successor) without Cause or by the Award Recipient for Good Reason, in each case, after a Change in Control.

In addition, in the event that the Award Recipient's Service is terminated by the Company without Cause or by the Award Recipient for Good Reason, in each case at least six (6) months following the Grant Date but prior to the occurrence of any of the Vesting Dates referenced in clauses (i)-(v) above, a *pro rata* portion of the Award will vest as of March 3<sup>rd</sup> of the calendar year following the year in which such termination occurs (or, if such termination occurs between January 1, 2029 and March 2, 2029, then on March 3, 2029) (such applicable March 3<sup>rd</sup> date, the "***Pro Rata Vesting Date***"), with the portion of the Award that vests equaling the product of (x) the Target Award Amount, <u>multiplied by</u> (y) the number of calendar days between the Grant Date and the date of termination divided by 1,096, <u>multiplied further by</u>, (z) the Pro Rata Performance Multiplier.

Any portion of the Award that does not vest will terminate automatically without any further action by the Company and be forfeited without further notice and at no cost to the Company upon the Award Recipient's termination of Service (or in the case of a termination provided for in the preceding paragraph, upon the Pro Rata Vesting Date). For the avoidance of doubt, the Award Recipient understands and acknowledges that the Award is not subject to any provisions in a Change in Control and Severance Agreement that define whether and in what manner Company equity incentives vest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Award Payment</u>. The amount payable pursuant to this Award will be payable as a lump sum cash payment as soon as practicable following the applicable Vesting Date, but in no event later than the sixtieth (60<sup>th</sup>) calendar day that immediately follows the first of such events.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>Additional Documents</u>. The Award Recipient agrees to execute such additional documents and complete and execute such forms as the Company may require for purposes of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)<u>Shareholder Rights</u>. The Award Recipient has no rights as a shareholder with respect to the Award. No adjustments shall be made for dividends, distributions, or other rights.

MACROBUTTON DocID \\4131-8922-2758 v4

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Incorporation of Plan</u>. The Award Recipient acknowledges receipt of the Plan, a copy of which is annexed hereto, and represents that he or she is familiar with its terms and provisions and hereby accepts this Award subject to all of the terms and provisions of the Plan and all interpretations, amendments, rules and regulations which may, from time to time, be promulgated and adopted pursuant to the Plan. The Plan is incorporated herein by reference. In the event of any conflict or inconsistency between the Plan and this Agreement, the Plan shall govern and this Agreement shall be interpreted to minimize or eliminate any such conflict or inconsistency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Restrictions on Transfer</u>. The Award may not be sold, transferred, assigned, transferred, pledged, hypothecated, or otherwise encumbered or disposed of, whether by operation of law or otherwise, nor may the Award be made subject to execution, attachment, or similar process. If the Award Recipient attempts to do any of these things, he or she will immediately and automatically forfeit the Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Withholding</u>. The Company or an Affiliate, as the case may be, shall have the right to deduct, from payments of any kind payable pursuant to this Award or otherwise due to the Award Recipient, any federal, state, or local taxes of any kind or other amounts required by Applicable Laws to be withheld in connection with the Award. The Company shall also have the right to require the Award Recipient to remit to the Company any and all amounts sufficient to satisfy any withholding or other taxes that may be due in connection with the Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>No Employment or Other Rights</u>. This Award does not confer upon the Award Recipient any right to be continued in the employment of, or otherwise provide Services to, the Company or any Subsidiary or other affiliate thereof, or interfere with or limit in any way the right of the Company or any Subsidiary or other affiliate thereof to terminate such Award Recipient's employment or other service relationship at any time. For purposes of this Agreement only, the term "employment" shall include circumstances under which the Award Recipient provides consulting or other Services to the Company or any of its Subsidiaries as an independent contractor, but such Award Recipient is not, nor shall be considered, an employee; provided, however, nothing in this Section 6 or this Agreement shall create an employment relationship between such person and the Company or its applicable Subsidiary, as the usages described in this Section are for convenience only.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<u>Discretionary Nature of Plan</u>. The Plan is discretionary in nature, and the Company may suspend, modify, amend or terminate the Plan in its sole discretion at any time, subject to the terms of the Plan and any applicable limitations imposed by Applicable Law. This Award under the Plan is a one-time benefit and does not create any contractual or other right to receive additional Awards or other benefits in lieu of other Awards in the future. Future grants, if any, will be at the sole discretion of the Committee, including, but not limited to, the timing of any grant, the amount of any Award granted, and the vesting provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.<u>Clawback/Recoupment</u>. By accepting this Award, the Award Recipient specifically agrees that any and all payments or benefits the Award Recipient or any other person may be entitled to receive under or as a result of this Award shall be immediately forfeited, and that the aggregate amount of any payments or benefits the Award Recipient or any other person has received under or as a result of this Award (determined without regard to any taxes or other amounts withheld from such payments or benefits), shall be repaid to the Company within 30 days following written notice from the Company (or such shorter period as may be required by Applicable Law), (1) as the Company in its discretion determines may be required to comply with any applicable listing standards of a national securities exchange adopted in accordance with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (regarding recovery of erroneously awarded compensation) and any implementing rules and regulations of the U.S. Securities and Exchange Commission (the "***SEC***") adopted thereunder or similar rules under the laws of any other jurisdiction, and (2) to the extent provided pursuant to the Company's Incentive Compensation Recovery Policy as in effect from time to time (which policy is filed or incorporated by reference annually with the SEC as Exhibit 97.1 to the Company's annual report on Form 10-K).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.<u>Section 409A</u>. The Award under this Agreement is intended to comply with Code Section 409A to the extent subject thereto, and, accordingly, to the maximum extent permitted, this Agreement will be interpreted and administered to be exempt from or in compliance with Code Section 409A. Notwithstanding anything to the contrary in the Plan or this Agreement, neither the Company, its Affiliates, the Board, nor the Committee will have any obligation to take any action to prevent the assessment of any excise tax or penalty on the Award Recipient under Code Section 409A, and neither the Company, its Affiliates, the Board, nor the Committee

MACROBUTTON DocID \\4131-8922-2758 v4

------

will have any liability to the Award Recipient for such tax or penalty. For purposes of this Agreement, a termination of Service occurs only upon an event that would be a "separation from service" within the meaning of Code Section 409A (a "***Section 409A Separation from Service***"). If, at the time of the Award Recipient's Section 409A Separation from Service, (1) the Award Recipient is a "specified employee" within the meaning of Code Section 409A, and (2) the Company makes a good faith determination that an amount payable on account of Award Recipient's Section 409A Separation from Service constitutes deferred compensation (within the meaning of Code Section 409A), the payment of which is required to be delayed pursuant to the six (6)-month delay rule set forth in Code Section 409A to avoid taxes or penalties under Code Section 409A (the "***Delay Period***"), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after the Delay Period (or upon Award Recipient's death, if earlier), without interest. Each Award installment that vests under this Agreement (if there is more than one installment) will be considered one of a series of separate payments for purposes of Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.<u>Miscellaneous Provisions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Applicable Law</u>. The validity, construction, interpretation and effect of this instrument will be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflicts of law provisions thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Notice</u>. Any notice required by the terms of this Agreement shall be delivered or made electronically, over the Internet or otherwise (with request for assurance of recipient in a manner typical with respect to communications of that type), or given in writing. Any notice given in writing shall be deemed effective upon personal delivery or upon deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, and shall be addressed to the Company at its principal executive office and to the Award Recipient at the address that he or she has most recently provided to the Company. Any notice given electronically shall be deemed effective on the date of transmission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Headings</u>. The headings of sections and subsections are included solely for convenience of reference and shall not affect the meaning of the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Counterparts</u>. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Amendments</u>. The Board and the Committee shall have the power to alter or amend the terms of Award as set forth herein from time to time, in any manner consistent with the provisions of the Plan, and any alteration or amendment of the terms of this Award by the Board or the Committee shall, upon adoption, become and be binding on all persons affected thereby without requirement for consent or other action with respect thereto by any such person. The Committee shall give notice to the Award Recipient of any such alteration or amendment as promptly as practicable after the adoption thereof. The foregoing shall not restrict the ability of the Award Recipient and the Board or the Committee by mutual written consent to alter or amend the terms of this Award in any manner which is consistent with the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Binding Effect</u>. This Agreement shall be binding upon the heirs, executors, administrators and successors of the Award Recipient and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>Entire Agreement</u>. This Agreement and the Plan constitute the entire agreement between the Award Recipient and the Company regarding this Award and supersede all prior arrangements or understandings (whether oral or written and whether express or implied) with respect thereto.

(*Remainder of page intentionally left blank*)

MACROBUTTON DocID \\4131-8922-2758 v4

------

## Exhibit 31.1

**Exhibit 31.1** 

**CERTIFICATION** 

I, Massimo Calafiore, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended March 31, 2026, of Orthofix Medical Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has material affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Dated: May 5, 2026 | By: | /s/ MASSIMO CALAFIORE |
|  | Name: | Massimo Calafiore |
|  | Title: | President and Chief Executive Officer, Director |

---

------

## Exhibit 31.2

**Exhibit 31.2** 

**CERTIFICATION** 

I, Julie Andrews, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended March 31, 2026, of Orthofix Medical Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has material affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Dated: May 5, 2026 | By: | /s/ JULIE ANDREWS |
|  | Name: | Julie Andrews |
|  | Title: | Chief Financial Officer |

---

------

## Exhibit 32.1

**Exhibit 32.1** 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO SECTION 906** 

**OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Quarterly Report of Orthofix Medical Inc. ("Orthofix") on Form 10-Q for the quarterly period ended March 31, 2026, (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, Massimo Calafiore, President and Chief Executive Officer, Director, and Julie Andrews, Chief Financial Officer, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Orthofix.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;Dated: May 5, 2026 | /s/ MASSIMO CALAFIORE | /s/ MASSIMO CALAFIORE |
|  | Name:  | Massimo Calafiore |
|  | Title:  | President and Chief Executive Officer, Director |
| &nbsp;&nbsp;&nbsp;&nbsp;Dated: May 5, 2026 | /s/ JULIE ANDREWS | /s/ JULIE ANDREWS |
|  | Name:  | Julie Andrews |
|  | Title:  | Chief Financial Officer |

---

------